UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March~~April 307, 2010

CERAGENIX PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

000-50470

84-1561463

(State or other jurisdiction

of incorporation)

Commission File

Number

(I.R.S. Employer Identification number)

1444 Wazee Street, Suite 210, Denver, Colorado 80202

(Address of principal executive offices, including zip code)

(720) 946-6440

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 Other Events

On ~~October~~ March 2630, ~~2009~~2010, the Company ~~issued~~filed a ~~press~~Current ~~release~~Report ~~announcing~~on ~~that~~Form 8-K ~~MAST BioSurgery~~providing ~~Inc~~a business update. Among ~~(“MAST”)~~other ~~had~~things, ~~decided~~the toCompany stated ~~invoke~~that ~~its~~it ~~right~~was todelinquent ~~negotiate commercialization~~in ~~terms~~making ~~pursuant~~certain payments to aBrigham ~~cooperative research and development~~Young ~~agreement~~University (~~the~~ “~~Agreement~~BYU”) ~~for~~and ~~one~~that orthese ~~more~~delinquent ~~new~~fees ~~surgical~~constituted ~~products~~grounds ~~incorporating~~for BYU to terminate the patent sublicense agreement between BYU and the Company~~’s CeraShield™~~ ~~antimicrobial~~(the “BYU ~~technology~~License”). ~~Under~~Further, the ~~terms~~Company ~~of the~~stated ~~Agreement,~~that ~~MAST~~it ~~had~~expected anBYU ~~exclusive~~to ~~sixty~~declare ~~(60)~~the ~~day~~Company ~~period~~ to ~~negotiate~~be ain ~~license~~default under the BYU ~~agreement~~License ~~for~~in the ~~Cerashield™~~near ~~technology~~future. On ~~within~~April 7, 2010, the ~~field~~Company ofreceived ~~use~~a asletter ~~defined~~from in BYU informing the ~~Agreement.~~Company Onthat ~~January 4,~~it ~~2010,~~was in breach of the ~~parties~~BYU ~~agreed~~License for failure to ~~extend~~keep ~~this exclusivity~~current ~~period~~on ~~until~~its ~~March 22,~~financial ~~2010~~obligations. On As ~~March 30,~~a ~~2010 (effective March 22~~result, ~~2010),~~ the Company ~~and~~has 30 days from ~~MAST~~receipt ~~agreed~~of the letter to ~~extend~~cure the ~~exclusive~~default ~~option~~or ~~period~~otherwise toface ~~June 22,~~termination ~~2010,~~of inthe ~~order~~agreement. The toCompany ~~allow~~will ~~MAST~~ require additional ~~time~~capital to ~~complete~~cure ~~its~~the ~~evaluation. There~~default, isthe noreceipt ~~assurance~~of ~~that~~which cannot be assured. A termination of the ~~parties~~BYU ~~will be~~License ~~able~~would tohave ~~reach~~a material anadverse ~~agreement~~affect on the ~~terms~~business prospects of athe ~~license agreement~~Company.

~~ITEM 9.01 Financial Statements and Exhibits~~SIGNATURES

~~None~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SIGNATURES

		Ceragenix Pharmaceuticals, Inc.

Dated:	April 9, 2010	/s/ Jeffrey Sperber
		Jeffrey Sperber, Chief Financial Officer

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.~~2

		Ceragenix Pharmaceuticals, Inc.
Dated:	March 31, 2010		/s/ Jeffrey Sperber
			Jeffrey Sperber, Chief Financial Officer

Filing Compare · CERAGENIX PHARMACEUTICALS, INC.